Skip to main content

Table 8 Validation of 4GV1 receptor with co crystallised inhibitors with the obtained marvel compound

From: Simulation studies, 3D QSAR and molecular docking on a point mutation of protein kinase B with flavonoids targeting ovarian Cancer

Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us